Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Vaccine Dose Optimization and Verification
NCT02704533Phase 1Completed
- Sponsor
- Sanaria Inc.
- Start
- Aug 2016
- Primary completion
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sanaria PfSPZ Vaccine in malaria (10 arms), sponsored by Sanaria Inc. Primary endpoints: Number or occurrence of at least possibly related Grade 3 AEs and serious adverse events (SAEs) for PfSPZ Vaccine at 14 months and PfSPZ Challenge (7G8) dose finding - Number or occurrence of at least possibly related Grade 3 AEs and SAEs at 140 days. Started Aug 2016; status: completed.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02704533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704533.